SanBio Company Limited (OTCMKTS:SNBIF – Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 1,533,629 shares, a growth of 19.6% from the February 12th total of 1,282,295 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ? days. Based on an average daily volume of 0 shares, the short-interest ratio is currently ? days.
SanBio Price Performance
Shares of SNBIF opened at C$10.11 on Monday. SanBio has a 52-week low of C$4.65 and a 52-week high of C$23.00. The business’s 50 day moving average price is C$10.11 and its two-hundred day moving average price is C$16.76.
Analysts Set New Price Targets
Separately, UBS Group started coverage on shares of SanBio in a research note on Sunday, December 14th. They set a “neutral” rating for the company. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold”.
About SanBio
SanBio Inc is a clinical?stage regenerative medicine company focused on developing proprietary cell therapies to address central nervous system disorders. The company’s core technology is based on modulating the brain’s innate repair mechanisms through the transplantation of adult stem cells, with the goal of restoring neurological function in patients suffering from conditions such as stroke, traumatic brain injury and neurodegenerative diseases.
The company’s lead product candidate, SB623, is an investigational cell therapy for chronic motor deficits following ischemic stroke.
Featured Articles
- Five stocks we like better than SanBio
- The $8,000 Gold Call Every Retirement Saver Needs to Read Right Now
- A personal warning from Martin Weiss (Please read)
- Elon Musk: This Could Turn $100 into $100,000
- America’s gold reserves are priced at $42. The real price is $6,000+.
- “This AI Giant is About to Go Bust”
Receive News & Ratings for SanBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SanBio and related companies with MarketBeat.com's FREE daily email newsletter.
